Roche to acquire Carmot Therapeutics for $2.7bn
Betsy Goodfellow | December 4, 2023 | News story | Business Services | Obesity, Roche, acquisition, diabetes
Roche has announced that it has entered into a definitive merger agreement with Carmot Therapeutics, in which it will acquire Carmot for an upfront price of $2.7bn as well as milestone payments up to $400m.
The acquisition will provide Roche with access to Carmot’s R&D portfolio, including clinical stage subcutaneous and oral incretins for the treatment of obesity in patients with and without diabetes, along with various preclinical programmes.
The treatments involved in the acquisition include:
- CT-388, a phase 2-ready, dual GLP-1/GIP receptor for the treatment of obesity in patients with and without type 2 diabetes
- CT-996, a once-daily oral, small molecule GLP-1 receptor agonist, which is currently in phase 1, intended for the treatment of obesity in patients with or without type 1 diabetes
- CT-868, a phase 2, once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist for the treatment of type 1 diabetes patients who are overweight or obese.
Existing clinical data for these assets is promising, demonstrating potential to achieve and maintain weight loss with differentiated efficacy. The drugs also provide an opportunity for combination treatments alongside Roche’s pipeline.
Thomas Schinecker, chief executive officer or Roche Group, commented: “Obesity is a heterogeneous disease, which contributes to many other diseases that together comprise a significant health burden worldwide. By combining Carmot’s portfolio with programmes in our Pharmaceuticals pipeline and our Diagnostics expertise and portfolio of products across cardiovascular and metabolic diseases, we are aiming to improve the standard of care and positively impact patients’ lives.”
Betsy Goodfellow
Related Content
First 90 days of antipsychotic treatment linked to rapid metabolic changes
The first 90 days after starting antipsychotic treatment are a critical period for monitoring blood …
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
Boehringer Ingelheim’s investigational survodutide produced weight loss of up to 13.1% after 76 weeks in …
Phoenix Labs acquires Kent Pharma
Phoenix Labs has acquired UK pharmaceutical distributor Kent Pharma from private equity firm Duke Street, …
